#Airdev canvas mobile app wrapper update#

And in Europe, our MAA was validated in March, and we expect approval about that time next year. We have a December 3 PDUFA date from the FDA. We expect our first global approval in Japan in the second half of the year. The company is set to receive 3 approvals within the next 12 months for Berotralstat. We are in an extraordinary position at BioCryst. Thank you, John, and thank you all for joining us this morning.

Stonehouse, BioCryst Pharmaceuticals, Inc. I’d now like to turn the call over to Jon Stonehouse. You should not place undue reliance on these forward-looking statements.įor additional information, including a detailed discussion of our risk factors, please refer to the company’s documents filed with the Securities and Exchange Commission, which can be accessed on our website. These statements are subject to known and unknown risks and uncertainties, which may cause our actual results, performance or achievements to be materially different from any future results or performance expressed or implied in this presentation. Following our remarks, we will answer your questions.īefore we begin, please note that today’s conference call will contain forward-looking statements, including those statements regarding future results, unaudited and forward-looking financial information as well as the company’s future performance and/or achievements. Bill Sheridan Chief Business Officer, Megan Sniecinski and Chief Commercial Officer, Charlie Gayer. Participating with me today are: CEO, Jon Stonehouse CFO, Anthony Doyle Chief Medical Officer, Dr. Today’s press release and slides are available on our website.

#Airdev canvas mobile app wrapper update#

And welcome to BioCryst’s First Quarter 2020 Corporate Update and Financial Results Conference Call. I would now like to turn the conference over to your host, Mr. And welcome to the BioCryst First Quarter 2020 Earnings Call.Īs a reminder, this conference call is being recorded. – Senior VP & Chief Business OfficerīioCryst Pharmaceuticals, Inc. – CEO, President & DirectorīioCryst Pharmaceuticals, Inc. – SVP of IR & Corporate CommunicationsīioCryst Pharmaceuticals, Inc. – Senior VP & Chief Commercial OfficerīioCryst Pharmaceuticals, Inc. – Senior VP & CFOīioCryst Pharmaceuticals, Inc. Manage your app directly with Microsoft Intune policies.BIRMINGHAM (Thomson StreetEvents) - Edited Transcript of BioCryst Pharmaceuticals Inc earnings conference call or presentation Wednesday, at 12: 30: 00pm GMTīioCryst Pharmaceuticals, Inc.Launch directly into your canvas app (no need to use app list).Set an image to show on the custom splash screen.You can distribute the app natively to your app users (for example, with Microsoft Intune).

This feature provides the following benefits:

Manage your app exclusively with Microsoft Intune policies.

Launch directly into your canvas app (no app list).

Set an image to show on the custom splash screen and sign in screens.

Provide your own home screen icon and app name.

Discoverability in the app store - your app gets its own unique Apple/Google app store identity (subject to channel policies).

With this feature, makers can publish their canvas apps as standalone, native mobile apps. Mobile Power Apps users have historically accessed company applications through the Power Apps mobile app for iOS and Android. Learn more: What's new and planned Enabled for Delivery timelines may change and projected functionality may not be released (see Microsoft policy). Some of the functionality described in this release plan has not been released.